Company Code: 1783 Company Name: HoKang Biotech Industry: Biotechnology and Medical Data Month/Year: 2026-02 Current Month Revenue: NT$47,965 Thousand (NT$0.48 Billion) YoY Change from Previous Year: +20.9%
FACT BOX
- Source: PR Times
- Category: 其他
其他
[HoKang Biotech] February 2026 Monthly Revenue: NT$0.48 Billion (YoY +20.9%)
Citation-Grade
Primary-source linked
Schema.org verified
NQ 67 / 100
Published Feb 1, 2026 9:00 AM ・ Updated Jun 1, 2026 12:15 PM ・ 2 min read ・ Source: PR Times
Show contents
⚡ Key Points
- HoKang Biotech (1783) announced its February 2026 revenue of NT$0.48 billion, achieving a year-on-year growth of 20.9%.
- The company, part of the biotechnology and medical industry, specializes in collagen and hyaluronic acid medical materials.
- This revenue increase reflects strong demand in the medical aesthetics and orthopedics markets.
HoKang Biotech (1783) announced its February 2026 revenue of NT$0.48 billion, achieving a year-on-year growth of 20.9%. The company, part of the biotechnology and medical industry, specializes in collagen and hyaluronic acid medical materials. This revenue increase reflects strong demand in the medical aesthetics and orthopedics markets.
Editorial & Verification Standards
The Washin AI News desk structures and reviews this article under the following standards.
- Start only from primary sources (official PR, disclosures, wire services)
- Numbers and proper nouns machine-checked against the source (number-completeness check)
- Company names and tickers verified via registry (Registry/TWSE/Wikidata)
- No speculation; nothing stated that is not in the source
Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›
- Announced Feb 1, 2026 9:00 AM — Distributor PR Times
- Collected Apr 7, 2026 8:00 AM
- AI structured & analyzed Apr 8, 2026 12:18 AM
- Desk-reviewed & published Feb 1, 2026 9:00 AM
FAQ
What are the key facts in this article?
HoKang Biotech (1783) announced its February 2026 revenue of NT$0.48 billion, achieving a year-on-year growth of 20.9%. The company, part of the biotechnology and medical industry, specializes in collagen and hyaluronic acid medical materials. This revenue increase reflects strong demand in the medical aesthetics and orthopedics markets.
Where is the primary source?
PR Times: https://openapi.twse.com.tw/revenue/twse-rev-1783-11502
When was it published?
Feb 1, 2026
Cite this article — HOW TO CITE
Washin AI News Desk“[HoKang Biotech] February 2026 Monthly Revenue: NT$0.48 Billion (YoY +20.9%)”AI News by Washin Village（和心村）, Feb 1, 2026. https://aeo.washinmura.jp/ai/%E5%92%8C%E5%BA%B7%E7%94%9F/en/news/2026-02-01-hokang-biotech-february-2026-monthly-rev
AI CRAWLER ACTIVITY
as of Jul 17, 2026
AI crawler visits to this article (cumulative)182 bots
Site-wide cumulative
Applebot
bot_visits_summary
4129k
last Jul 17, 2026
ClaudeBot
bot_visits_summary
3019k
last Jul 17, 2026
GPTBot
bot_visits_summary
2582k
last Jul 17, 2026
Bingbot
bot_visits_summary
2448k
last Jul 17, 2026
Meta AI
bot_visits_summary
1010k
last Jul 17, 2026
Google AI
bot_visits_summary
687k
last Jul 17, 2026
※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.
Washin AI News（AI News by Washin Village（和心村））
An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.
Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification
Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →